Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pablo Garcia

Showing results (401-410 of 455) with videos related to

Pageof 46
Sort By:
JAMA Cardiology|November 8, 2025
Efficacy of Acoramidis in Wild-Type and Variant Transthyretin Amyloid Cardiomyopathy: Results From ATTRibute-CM and Its Open-Label ExtensionKevin M Alexander, Margot K Davis, Olakunle Akinboboye, et al.
JACC. Heart Failure|October 19, 2024
Genetic Landscape of Patients With Dilated Cardiomyopathy and a Systemic Immune-Mediated DiseaseSophie L V M Stroeks, Michiel T H M Henkens, Fernando Dominguez, et al.
The New England Journal of Medicine|September 1, 2025
Aficamten or Metoprolol Monotherapy for Obstructive Hypertrophic CardiomyopathyPablo Garcia-Pavia, Martin S Maron, Ahmad Masri, et al.
JAMA Neurology|September 24, 2019
Medical Management vs Mechanical Thrombectomy for Mild Strokes: An International Multicenter Study and Systematic Review and Meta-analysisNitin Goyal, Georgios Tsivgoulis, Konark Malhotra, et al.
Journal for Immunotherapy of Cancer|September 22, 2022
Shorter versus longer corticosteroid duration and recurrent immune checkpoint inhibitor-associated AKIShruti Gupta, Clara Garcia-Carro, Jason M Prosek, et al.
Journal of the American College of Cardiology|December 5, 2025
Aficamten in Obstructive Hypertrophic Cardiomyopathy: A Multidomain, Patient-Level Analysis of the MAPLE-HCM TrialAndrew Wang, Pablo Garcia-Pavia, Ahmad Masri, et al.
European Heart Journal|August 28, 2023
Emery-Dreifuss muscular dystrophy Type 1 is associated with a high risk of malignant ventricular arrhythmias and end-stage heart failureDouglas E Cannie, Petros Syrris, Alexandros Protonotarios, et al.
European Heart Journal|October 27, 2015
Hypertrophic remodelling in cardiac regulatory myosin light chain (MYL2) founder mutation carriersGodelieve R F Claes, Florence H J van Tienen, Patrick Lindsey, et al.
Journal of the American College of Cardiology|September 11, 2025
Effect of Aficamten Compared With Metoprolol on Echocardiographic Measures in Symptomatic Obstructive Hypertrophic Cardiomyopathy: MAPLE-HCMSheila M Hegde, Xiaowen Wang, Pablo Garcia-Pavia, et al.
Journal of the American College of Cardiology|November 17, 2018
Dilated Cardiomyopathy Due to BLC2-Associated Athanogene 3 (BAG3) MutationsFernando Domínguez, Sofía Cuenca, Zofia Bilińska, et al.
Pageof 46

Showing results (401-410 of 455) with videos related to

Sort By:
Pageof 46
JAMA Cardiology|November 8, 2025
Efficacy of Acoramidis in Wild-Type and Variant Transthyretin Amyloid Cardiomyopathy: Results From ATTRibute-CM and Its Open-Label ExtensionKevin M Alexander, Margot K Davis, Olakunle Akinboboye, et al.
JACC. Heart Failure|October 19, 2024
Genetic Landscape of Patients With Dilated Cardiomyopathy and a Systemic Immune-Mediated DiseaseSophie L V M Stroeks, Michiel T H M Henkens, Fernando Dominguez, et al.
The New England Journal of Medicine|September 1, 2025
Aficamten or Metoprolol Monotherapy for Obstructive Hypertrophic CardiomyopathyPablo Garcia-Pavia, Martin S Maron, Ahmad Masri, et al.
JAMA Neurology|September 24, 2019
Medical Management vs Mechanical Thrombectomy for Mild Strokes: An International Multicenter Study and Systematic Review and Meta-analysisNitin Goyal, Georgios Tsivgoulis, Konark Malhotra, et al.
Journal for Immunotherapy of Cancer|September 22, 2022
Shorter versus longer corticosteroid duration and recurrent immune checkpoint inhibitor-associated AKIShruti Gupta, Clara Garcia-Carro, Jason M Prosek, et al.
Journal of the American College of Cardiology|December 5, 2025
Aficamten in Obstructive Hypertrophic Cardiomyopathy: A Multidomain, Patient-Level Analysis of the MAPLE-HCM TrialAndrew Wang, Pablo Garcia-Pavia, Ahmad Masri, et al.
European Heart Journal|August 28, 2023
Emery-Dreifuss muscular dystrophy Type 1 is associated with a high risk of malignant ventricular arrhythmias and end-stage heart failureDouglas E Cannie, Petros Syrris, Alexandros Protonotarios, et al.
European Heart Journal|October 27, 2015
Hypertrophic remodelling in cardiac regulatory myosin light chain (MYL2) founder mutation carriersGodelieve R F Claes, Florence H J van Tienen, Patrick Lindsey, et al.
Journal of the American College of Cardiology|September 11, 2025
Effect of Aficamten Compared With Metoprolol on Echocardiographic Measures in Symptomatic Obstructive Hypertrophic Cardiomyopathy: MAPLE-HCMSheila M Hegde, Xiaowen Wang, Pablo Garcia-Pavia, et al.
Journal of the American College of Cardiology|November 17, 2018
Dilated Cardiomyopathy Due to BLC2-Associated Athanogene 3 (BAG3) MutationsFernando Domínguez, Sofía Cuenca, Zofia Bilińska, et al.
Pageof 46